Tissue-protective peptide
ARA-290 (Cibinetide)
ARA-290 (cibinetide) has a reported plasma half-life of about 2 minutes in a 2015 review, against the app's 2 hours.1
ARA-290 (Cibinetide) after one dose: 50% at ~2 h, 25% at 4 h, 12.5% at 6 h.
Drawn from the half-life in the app's model, ~2 h. The model's figures
- Compound
- ARA-290 (Cibinetide)
- Symbol
- ARA
- Family
- Healing peptides
- Parts
- 13
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
ARA-290, also called cibinetide and pHBSP, is described in a 2015 review as an 11 amino acid peptide modeled on the helix B region of erythropoietin.1 The review says erythropoietin derivatives have been developed which "selectively activate the IRR without interacting with the EPOR homodimer", and a trial report calls ARA290 "an EPO-analog peptide without such hematopoietic side-effects".1,2 Two of the review's four authors, Cerami and Brines, are listed with Araim Pharmaceuticals.1
The human trials identified in PubMed and ClinicalTrials.gov enrolled between 9 and 64 people each. Authors affiliated with Araim Pharmaceuticals appear on the sarcoidosis, type 2 diabetes and macular edema trials, and the company is described as "developing cibinetide for clinical use".3,4,5,6,7 The app grades the evidence for ARA-290 as emerging, and the app lists it as a tissue-protective peptide studied mainly for small-fiber and diabetic neuropathy.
How it works
Sources in this part
A 2015 review states that a heterodimer of the erythropoietin receptor and the β common receptor, termed the innate repair receptor, "activates tissue protection and repair".1 The review adds that this receptor "is typically not expressed by normal tissues, but instead is rapidly induced by injury or inflammation".1 A Leiden trial report cites preclinical and in vitro studies showing that "activation of the IRR requires concentrations of ARA 290 greater than or equal to ~1 nmol/L (~1.3 ng/mL)".4 The review says the peptide "triggers sustained biological effects" despite its short half-life.1
Animal study: spared nerve injury in rats
This part describes rats, not people. Swartjes and colleagues (Leiden University Medical Center and Araim Pharmaceuticals, Molecular Pain, 2014) gave rats vehicle or ARA290 at 3, 10, 30 or 60 μg/kg on days 1, 3, 6, 8 and 10 after a spared nerve injury.8 The authors report that ARA290 "exerted a dose-response effect by significantly reducing mechanical allodynia up to 20 weeks when compared to vehicle", and that the 3 and 10 μg/kg doses did not produce significant relief of mechanical allodynia (P = 0.825 and 0.707).8 The same paper reports that the reduction of cold allodynia was significant up to 20 weeks at 3, 10, 30 and 60 μg/kg, that animals treated with 30 μg/kg did not show increased microglia reactivity at 20 weeks while those treated with 0 and 10 μg/kg did, and that no difference in astrocyte reaction was observed.8 They call the coupling to suppression of the spinal microglia response "suggestive of a mechanistic link".8
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2 h
- Bioavailability
- 90%
- Typical dose
- 2–4 mg/day
- Route
- SubQ
- Time to peak
- ~0.5 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 2 hours (the app's figure) | A plasma half-life of about 2 minutes in a 2015 review; a "short serum half-life of a few minutes" in a 2012 trial report; a terminal half-life of ~20 min after 4 mg subcutaneously in normal volunteers, cited in a 2015 type 2 diabetes trial report1,3,5 |
| Bioavailability | 90% by subcutaneous injection (the app's figure) | The sources read give no bioavailability figure; a 10-volunteer crossover reported median areas under the curve, counted only while concentrations exceeded 1.3 ng/mL, of 65 ng/mL × min for 2 mg intravenous, 23 for 2 mg subcutaneous, 59 for 4 mg subcutaneous and 249 for 6 mg subcutaneous4 |
| Time to peak | About 0.5 hours (the app's figure) | The sources read give no time to peak; they give peak concentrations of about 50 ng/mL after 2 mg intravenously in normal volunteers, about 3 ng/mL (~2.4 nmol/L) after 4 mg subcutaneously in normal volunteers, and about 1.8 nM after 4 mg subcutaneously in non-obese subjects3,5,7 |
| Metabolism | Not stated by the app | In an in vitro experiment with blood specimens, "extensive exopeptidase-driven metabolism was observed for ARA-290 (with one main metabolite PyrEQLERALN)"; this is a laboratory finding, not a measurement in people9 |
Human studies
The trials below are listed by year; each is described in more detail afterwards, with its sponsor and the authors' ties to it.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Heij and colleagues, Molecular Medicine 20123 | Double-blind, placebo-controlled exploratory trial; ARA 290 supplied by Araim Pharmaceuticals3 | 22 people with sarcoidosis and symptoms of small fiber neuropathy3 | 2 mg intravenously three times weekly or placebo, 4 weeks (12 on ARA 290, 10 on placebo)3 | Small fiber neuropathy screening list score changed by Δ -11.5 ± 3.04 with ARA 290 against Δ -2.9 ± 3.34 with placebo (SEM); Brief Pain Inventory pain scores improved equivalently in both groups3 |
| Dahan and colleagues, Molecular Medicine 20134 | Investigator-initiated, single-site, double-blind, placebo-controlled trial; Dutch government grant; Araim-employed authors4 | 38 people with sarcoidosis and neuropathic symptoms, mean age 49.5 years4 | 4 mg subcutaneously daily or placebo for 28 days, 16 weeks of follow-up4 | Median corneal nerve fiber area rose 14.5% (185 μm2; p = 0.022) against a non-significant fall of 5.3% with placebo; the intraepidermal nerve fiber change in the distal leg was not significant (p = ns)4 |
| Brines and colleagues, Molecular Medicine 20155 | Phase 2, placebo-controlled; Dutch government and Swedish grants; Araim officers among the authors5 | 49 people with type 2 diabetes and painful distal extremities enrolled; 48 analysed5 | 4 mg subcutaneously daily or placebo for 28 days, then 28 days without treatment5 | PainDetect improved 3.3 points against 1.1 with placebo (p = 0.037); hemoglobin A1c fell 0.16% against 0.01% at day 28; overall corneal nerve fiber density change was non-significant; four serious adverse events on ARA 290, one death5 |
| Culver and colleagues, Investigative Ophthalmology and Visual Science 20176,10 | Phase 2b, randomized, dose ranging, placebo-controlled; registry lists Araim Pharmaceuticals as lead sponsor6,10 | 64 people with sarcoidosis-associated small nerve fiber loss and neuropathic pain6 | 1, 4 or 8 mg/day or placebo, 28 days, 12 weeks of follow-up6,10 | Placebo-corrected change in corneal nerve fiber area 109 μm2 (95% CI -429, 647) at 1 mg, 697 (159, 1236; P = 0.012) at 4 mg and 431 (-130, 992) at 8 mg6 |
| Lois and colleagues, Journal of Clinical Medicine 20207,11 | Single-arm phase 2 pilot, descriptive statistics; funded in part by Araim Pharmaceuticals7 | 9 recruited with diabetic macular edema, 8 completed7 | 4 mg/day subcutaneously, 12 weeks7 | No improvement in mean visual acuity, retinal thickness, retinal sensitivity or tear production; questionnaire composite score +2.7 + 3.1; all 9 had at least one adverse event, no serious ones7 |
| Cerit and colleagues, European Neuropsychopharmacology 20152 | Double-blind, randomized, parallel-group2 | 36 healthy volunteers2 | 2 mg or placebo, assessed one week after administration2 | Lower neural responses to happy faces in the fusiform gyrus; no effects on mood and affective symptoms2 |
Deeper analysis: Heij 2012 sarcoidosis pilot
Heij and colleagues at Leiden University Medical Center reported this trial in Molecular Medicine in 2012, enrolling 22 people with sarcoidosis, a neuropathy diagnosis and a spontaneous Brief Pain Inventory pain score of 5 or more.3 Three people withdrew because of "the inconvenience of intravenous infusions" (one on ARA 290, two on placebo) and were replaced by alternates recruited as backups.3 Missing data points were handled by last observation carried forward.3 The screening list score fell by Δ -11.5 ± 3.04 with ARA 290 and Δ -2.9 ± 3.34 with placebo, and 42% of ARA 290 recipients improved by 15 points or more against none on placebo.3 The secondary and null results were these: the Brief Pain Inventory and fatigue scores "improved significantly but equivalently in both patient groups", the depression score did not change, and the pain part of the screening list improved similarly but "the magnitude was not significantly different from that observed for the placebo group".3 On safety, the authors write that patients "tolerated repeated intravenous infusions of ARA 290 without adverse events noted by study personnel or self-reported", with hemoglobin 8.7 ± 0.19 mmol/L on ARA 290 and 8.7 ± 0.34 on placebo at week 4.3 The authors name "the small sample size, patient variability of neuropathic involvement and lack of skin biopsy or sudomotor testing evidence definitively establishing SFN" as primary limitations, and say the reduction in symptom severity "cannot be attributed with certainty only to effects of ARA 290 on small fiber function".3 The trial was "investigator-initiated" with ARA 290 supplied by Araim Pharmaceuticals, and three authors (Dunne, Brines and Cerami) are employees and officers of the company who own stock or options.3
Deeper analysis: Dahan 2013 sarcoidosis trial, 4 mg subcutaneously
Dahan and colleagues (Leiden University Medical Center with Araim Pharmaceuticals, Molecular Medicine, 2013) ran an investigator-initiated, single-site, double-blind, placebo-controlled trial registered as NTR3575.4 It enrolled 38 people with sarcoidosis and neuropathic symptoms, all of whom "had failed existing therapy for neuropathy".4 The median corneal nerve fiber area rose by 14.5% (185 μm2, p = 0.022) on ARA 290, while the placebo group had "a nonsignificant decrease" of 5.3%.4 The skin biopsy result was not significant: the distal-leg intraepidermal fiber density rose 0.38 ± 0.48 fibers/mm on ARA 290 (p = ns) and the thigh density fell in both groups (p = ns); retinal thickness and visual acuity did not change.4 Among the secondary outcomes, the screening list score fell 12.2 ± 1.9 on ARA 290 against 3.8 ± 2.1 on placebo at week 5 (p = 0.005); the average Brief Pain Inventory pain intensity "was reduced ~9% from baseline in both treatment groups" with no significant difference between them; and the 6-minute walk distance rose a mean 18.7 m on ARA 290 against a fall of 15.1 m on placebo (p = 0.049).4 At 9 months after dosing the 6-minute walk change from baseline was not significant in either group.4 For safety, "No serious adverse events were encountered during the dosing period or within the 12 wks of follow-up"; three moderate events occurred on placebo (diarrhea, irritability, light-headedness), and one person on ARA 290 had a moderate event of long-term weight loss of 14 kg that, the authors write, began before study entry.4 The authors give as "principal limitations" that "only patients with pain were studied, and these patients did not have known active sarcoid involvement of any other organ", and add that about 30% of patients used other neuropathy drugs during the trial, so combined effects could not be assessed.4 Funding was in part a Dutch government grant, and Dunne, Cerami and Brines are employees of Araim Pharmaceuticals with stock or options.4
Deeper analysis: Brines 2015 type 2 diabetes trial
Brines and colleagues (Araim Pharmaceuticals and Leiden, Molecular Medicine, 2015) screened 61 people with diabetes and painful distal extremities, enrolled 49, and analysed 48 after one person stopped at day 15 because of worsening borderline renal insufficiency.5 Hemoglobin A1c was analysed for 42 people with complete values, whose mean baseline was 7.3% on ARA 290 and 6.9% on placebo, and the change from baseline at day 28 and day 56 was −0.16% and −0.21% on ARA 290 against −0.01% and +0.21% on placebo (p = 0.002, repeated measures ANOVA).5 The PainDetect score improved 3.3 points on ARA 290 against 1.1 on placebo (p = 0.037).5 The null and secondary results were: both groups improved by about 20% on the Neuropathic Pain Symptom Inventory at day 28, neither group changed on the screening list score, the 6-minute walk rose 3.5% of baseline on ARA 290 (p = 0.09), and quantitative sensory testing showed no significant differences after treatment.5 Corneal nerve fiber density rose by a non-significant 1.1 ± 1.1 fibers/mm2 on ARA 290 against 0.1 ± 1.2 on placebo; a post hoc subgroup with reduced density at baseline rose +2.6 ± 1.0 (n = 18; p = 0.02) against +0.7 ± 1.3 on placebo (n = 19; p = ns).5 The paper's summary reads "No potential safety issues were identified", while the results report four serious adverse events on ARA 290: two judged unlikely to be related, one worsening renal insufficiency in a person on furosemide (creatinine 119 to 159 μmol/L, treatment stopped by the safety committee), and a 70-year-old man with severe cellulitis two weeks after the last dose who had a fatal myocardial infarction, judged by the safety committee unrelated to ARA 290.5 The authors list "two major limitations": "the treatment duration was only for 28 d and the subjects were under generally excellent metabolic control".5 Funding was in part a Dutch government grant to the Netherlands Institute for Regenerative Medicine with Swedish sources, and Brines, Dunne and Cerami are officers of Araim Pharmaceuticals who own stock or options.5 A separate registry entry for a Karolinska Institutet phase 2 study of ARA 290 in prediabetes and type 2 diabetes (NCT01933529), which lists Araim Pharmaceuticals, Inc. as a collaborator, has the status UNKNOWN and was not matched to a published paper.12
Deeper analysis: Culver 2017 phase 2b dose-ranging trial
Culver and colleagues (Cleveland Clinic, Leiden, Manchester, Weill Cornell Medicine-Qatar and Araim Pharmaceuticals; Investigative Ophthalmology and Visual Science, 2017) randomized 64 people to cibinetide 1, 4 or 8 mg/day or placebo for 28 days, with change in corneal nerve fiber area as the primary endpoint.6 Only the PubMed record of this paper was read, so its limitations section and funding statement were not seen. The placebo-corrected change in corneal nerve fiber area was 109 μm2 (95% CI -429 to 647) at 1 mg, 697 μm2 (159 to 1236; P = 0.012) at 4 mg and 431 μm2 (-130 to 992) at 8 mg, so only the 4 mg interval excluded zero.6 Intraepidermal GAP-43+ fibers "increased in the 4 mg group (P = 0.035)".6 Pain "improved significantly in all groups", and the clinically meaningful placebo-corrected decrease in pain intensity in the 4 mg group among those with moderate to severe pain had P = 0.157, which is not statistically significant.6 The authors conclude that cibinetide "significantly increased small nerve fiber abundance in the cornea and skin, consistent with a disease modifying effect".6 The registry names Araim Pharmaceuticals, Inc. as lead sponsor and shows 16 started in each arm, with 16, 15, 13 and 16 completing (1, 4, 8 mg and placebo), the 8 mg arm including one withdrawal for an adverse event.10 The registry's serious adverse event terms include syncope, headache, chest tightness, shortness of breath, small bowel enteritis and suicidal ideation.10
Deeper analysis: Lois 2020 diabetic macular edema pilot
Lois and colleagues (Belfast Health and Social Care Trust with Araim Pharmaceuticals, Journal of Clinical Medicine, 2020) recruited people between May 2016 and April 2017 who self-administered cibinetide 4 mg/day subcutaneously for 12 weeks.7 The registry entry lists the Belfast Health and Social Care Trust as lead sponsor.11 The registry status is TERMINATED, and the stated reason is expiry of the study drug with no replacement available.11 Nine were recruited and eight completed; there was "no improvement" in mean visual acuity (-2.9 + 5.0), central retinal thickness (10 + 94.6 microns), central retinal sensitivity (-0.53 + 1.9 dB) or tear production (-0.13 + 7.7 mm), while the visual function questionnaire composite score changed by 2.7 + 3.1.7 In individual eyes, central retinal thickness fell in five of eight study eyes and rose in three.7 All people had at least one adverse event and none had a serious one; the most frequent were increased triglycerides (5/9), headache (4/9), head cold (4/9), increased glucose (3/9), nausea (2/9), decreased BCVA (2/9), pneumonia (1/9) and staphylococcus aureus of toe (1/9), with headache, head cold and nausea "felt to be potentially related to the study drug"; the authors write that, since fasting status was not confirmed, the triglyceride and glucose elevations "may have been postprandial effects".7 The report states "Subcutaneous administration was well-tolerated".7 The authors list as limitations "its pilot nature, very small number of patients included, lack of control group and very short duration of follow-up", and raise the fixed 4 mg dose as a "potential confounder".7 Funding was "in part by Araim Pharmaceuticals" and the chief investigator's own research fund; Kirk, Dunne, Cerami and Brines are officers who own stock in Araim, and Bajorunas is a clinical development consultant for it.7
Healthy volunteers: emotional processing
Cerit and colleagues (Leiden University, Oxford and Copenhagen, European Neuropsychopharmacology, 2015) tested 36 healthy participants, and the PubMed record lists no Araim affiliation.2 The authors conclude that "the direction and the strength of its effects do not unequivocally support an antidepressant-like profile for ARA290", and suggest future studies of "different timing and dose".2 The paper also reports that ARA290 tended to lower the recognition of happy and disgust facial expressions, was associated with faster categorization of positive vs negative words and was not associated with a better memory for positive words; only the PubMed record of this paper was read, so its limitations and funding were not seen.2
Doses reported in studies and on labels
These are doses used in named studies, listed as reported; a DailyMed search for "cibinetide" on 16 November 2026 returned no labels, so no label dose is listed.
| Source | Dose and route | Length and comparator | People |
|---|---|---|---|
| Heij 20123 | 2 mg intravenously, three times weekly | 4 weeks, placebo | 12 on ARA 290, 10 on placebo |
| Dahan 20134 | 4 mg subcutaneously, daily | 28 days, placebo | 38 enrolled |
| Brines 20155 | 4 mg subcutaneously, daily, self-administered | 28 days, then 28 days without treatment, placebo | 49 enrolled, 48 analysed |
| Culver 201710 | 1, 4 or 8 mg subcutaneously, daily | 28 days, placebo (formulation buffer) | 64 |
| Lois 20207 | 4 mg/day subcutaneously, self-administered | 12 weeks, no control group | 9 recruited, 8 completed |
| Cerit 20152 | 2 mg, route not stated in the PubMed record | Placebo-controlled, assessed one week after administration | 36 healthy |
Side effects reported
The 2012 Leiden pilot reports no adverse events noted by study personnel or self-reported, while the 2013 Leiden trial reports no serious adverse events, three moderate events on placebo, one moderate event on ARA 290 (a long-term weight loss of 14 kg that, the authors write, began before study entry) and "Multiple, mild adverse events" none judged likely related.3,4 The 2015 type 2 diabetes trial reports four serious adverse events on ARA 290, two judged unlikely and two judged possibly related to ARA 290; the two described are a worsening of borderline renal insufficiency, after which the safety committee stopped ARA 290, and a fatal myocardial infarction that the safety committee judged unrelated, and adverse events were categorised as 54 mild, 9 moderate and 1 severe on ARA 290 against 61 mild and 5 moderate on placebo.5 The 2017 dose-ranging trial's registry results list serious adverse events in 2 of 16 on 1 mg, none on 4 mg, 1 of 14 on 8 mg and none on placebo, including one suicidal ideation event.10 The 2020 macular edema pilot reports at least one adverse event in each of 9 people, with no serious adverse events.7
Bloodwork and markers
Sources in this part
The sarcoidosis pilot measured hemoglobin, and the authors report 8.9 ± 0.21 mmol/L on ARA 290 against 8.6 ± 0.26 on placebo at baseline and 8.7 ± 0.19 against 8.7 ± 0.34 at week 4.3 Anti-ARA 290 antibodies were tested in the 2013, 2015 and 2020 trials, and none were reported.4,5,7 The diabetes trial reported "No clinically significant changes from baseline values of the hematology or clinical chemistry", and a lower cholesterol to HDL ratio (p = 0.039) and triglycerides (p = 0.043) on ARA 290, with triglyceride samples "not performed on fasting serum samples".5
Regulatory and anti-doping status
Sources in this part
A search of DailyMed on 16 November 2026 for "cibinetide" returned no labels, and no label for ARA-290 was identified; other regulators' registers were not searched. A 2017 doping-control paper from the German Sport University Cologne describes "the prohibited peptides ARA-290, GHRP-3, and Peforelin" in an in vitro metabolism study.9 The World Anti-Doping Agency's 2026 Prohibited List, in section S2.1.5, names "Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO)", and the list says substances "with similar chemical structure or similar biological effect(s), are prohibited".13 The 2026 list text read does not name ARA-290 or cibinetide.13
What is not known
The longest dosing period in the trials identified was 12 weeks, in a single-arm pilot of 9 people, and the controlled trials lasted 28 days or 4 weeks.7,4,3 No trial in people reporting hard clinical outcomes was identified in PubMed or ClinicalTrials.gov; the 2017 sarcoidosis trial authors describe corneal nerve fiber area and regenerating intraepidermal fibers as "surrogate endpoints for disease modification, pain severity, and functional capacity".6 The sarcoidosis, type 2 diabetes and macular edema trials each list authors affiliated with Araim Pharmaceuticals, and a trial run without such authors that reports efficacy in these conditions was not identified.3,4,5,6,7 The app's half-life of about 2 hours differs from the review's about 2 minutes and from the terminal half-life of ~20 min after 4 mg subcutaneously that a 2015 trial report cites for normal volunteers; no human plasma concentration curve was read in the sources.1,5 The sources read give neither the app's 90% subcutaneous bioavailability nor its 0.5 hour time to peak.
Frequently asked questions
What is ARA-290?
ARA-290, also called cibinetide and pHBSP, is an 11 amino acid peptide modeled on the helix B region of erythropoietin.1
What is the half-life of ARA-290?
Did the sarcoidosis trials reach their endpoints?
The 64-person phase 2b trial's primary endpoint was the change in corneal nerve fiber area at 28 days, and only the 4 mg group had an interval that excluded zero.6 In the 2012 pilot of 22 people the screening list score improved more than with placebo, while the Brief Pain Inventory pain score improved equivalently in both groups.3 In the 2013 trial of 38 people the median corneal nerve fiber area rose 14.5% on ARA 290 against a non-significant fall of 5.3% on placebo, the distal-leg intraepidermal nerve fiber change was not significant, and the average Brief Pain Inventory pain intensity was reduced about 9% from baseline in both groups.4
Has ARA-290 been studied in diabetic macular edema?
A 9-person phase 2 trial of cibinetide 4 mg/day for 12 weeks reported no improvement in mean visual acuity, central retinal thickness, central retinal sensitivity or tear production.7 The same report gives an improvement in the visual function questionnaire composite score (2.7 + 3.1), in a trial with no control group that was funded in part by Araim Pharmaceuticals.7 The registry lists the trial as terminated, with the reason "Expiry of study drug - no replacement available."11
What side effects were reported in ARA-290 trials?
Trial reports differ: the 2012 pilot reported no adverse events noted by study personnel or self-reported, all 9 people in the 2020 macular edema pilot had at least one adverse event with no serious ones, and the 2015 type 2 diabetes trial reported four serious adverse events on ARA 290, one of them a fatal myocardial infarction that the safety committee judged unrelated.3,7,5
Who sponsored the ARA-290 trials?
Araim Pharmaceuticals is the registry's lead sponsor for the 64-person sarcoidosis trial and funded the macular edema pilot in part.10,7 Dunne, Brines and Cerami are described as employees and officers of Araim Pharmaceuticals who own stock or options in the 2012 pilot, as employees with stock or options in the 2013 trial, and as officers who own stock or options in the 2015 type 2 diabetes trial; the registry lists the Belfast Health and Social Care Trust as lead sponsor of the macular edema pilot.3,4,5,11
Guides, tools and comparisons
References
- Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther 2015. PMID 25728128
- Cerit H, Veer IM, Dahan A, et al. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. Eur Neuropsychopharmacol 2015. PMID 26431906
- Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012. PMID 23168581
- Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013. PMID 24136731
- Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 2015. PMID 25387363
- Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci 2017. PMID 28475703
- Lois N, Gardner E, McFarland M, et al. A phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema. J Clin Med 2020. PMID 32674280
- Swartjes M, van Velzen M, Niesters M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain 2014. PMID 24529189
- Thomas A, Knoop A, Schänzer W, Thevis M. Characterization of in vitro generated metabolites of selected peptides below 2 kDa prohibited in sports. Drug Test Anal 2017. PMID 28941172
- ClinicalTrials.gov. NCT02039687. Study of efficacy of ARA 290 on corneal nerve fiber density and neuropathic symptoms of subjects with sarcoidosis. NCT02039687
- ClinicalTrials.gov. NCT06626971. The use of ARA290 for the treatment of diabetic macular oedema. NCT06626971
- ClinicalTrials.gov. NCT01933529. ARA290 in T2D: effects of ARA 290, an erythropoietin analogue, in prediabetes and type 2 diabetes. NCT01933529
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list